Clinical trials: Human Immunodeficiency Virus Transmission
Diabetes, HIV Infections
The Study of HIV Protease Inhibitors and Their Effects on Glucose Metabolism
The purpose of this study is to determine the mechanisms by which HIV protease inhibitors contribute to the development of diabetes in HIV-infected patients.
- Conditions
- Diabetes, HIV Infections, Insulin Resistance
- Trial name
- NCT00259727
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
Human Immunodeficiency Virus
Evaluation of Kaletra Therapy Over the Long-term
Long term observation of patients under lopinavir/ritonavir containing therapy
- Trial name
- NCT01083810
- Testing
- Lopinavir/Ritonavir (Kaletra)
- Where
- 90 sites in Germany
- Volunteers
- 284 people
- Sponsor
- Abbott
Infection, Human Immunodeficiency Virus
A Study of the Relative Bioavailability of BMS-626529 Administered as BMS-663068 From 150mg Low-dose Extended-release Tablets Compared to 600mg Reference Extended-release Tablets in Healthy Subjects
An oral dose in healthy subjects to determine the relative bioavailabilty of BMS-626529 administered as BMS-663068
- Trial name
- NCT02859259
- Testing
- BMS-663068 (1 tablet at 600 mg), BMS-663068 (4 tablets at 150 mg each tablet)
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Antiretroviral Treatment, HIV Infection
Incidence of Metabolic Syndrome in People Living With HIV Without ExperienCe to ART Who Start DoLutegravir Based-Regimen Compared With BictegrAvir Based-RegimeN
The aim of the study was to identify the incidence of MetS at 48 weeks for ATP III score in patients living with HIV (PLH) who started antiretroviral therapy (ART) with Dolutegravir based-regimen compared with Bictegravir…
- Conditions
- Antiretroviral Treatment, HIV Infection, Metabolic Cardiovascular Syndrome
- Trial name
- MICTLAN (NCT06629480)
- Testing
- Bictegravir
- Where
- Mexico
- Volunteers
- 378 people
- Sponsor
- Instituto Mexicano del Seguro Social
HIV Infections, Liver Toxicity
Compare to the Safety of Efavirenz and Nevirapine in Treating HIV Positive Patients With Mild Baseline Liver Function Test Impairment, and/or Hepatitis B or Hepatitis C Co-infection
The purpose of this study is to demonstrate the difference in frequency and level of liver function disturbance between patients on efavirenz based ART, and patients on nevirapine based ART in HBV and HCV co-infected patients…
- Conditions
- HIV Infections, Liver Toxicity, Hepatitis Co-infection
- Trial name
- NCT01273142
- Volunteers
- 100 people
- Sponsor
- Henan Provincial People's Hospital
HIV
Immunologic and Virologic Parameters During Analytical Treatment Interruption Following Combination bNAb Therapy During Suppressive ART
Background: Recent studies have shown bNAbs may help remove cells that are infected with HIV (HIV reservoir) from the body and may also change how the immune system fights HIV.
- Trial name
- NCT06908083
- Testing
- Analytical Treatment Interruption
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV/AIDS
Risk of CV Events With EFV vs. EFV-free Regimens
The purpose of this study is to determine whether there is an increased risk of cardiovascular events (CV) with regimens containing efavirenz (EFV) versus other regimens in patients with HIV.
- Trial name
- NCT02426866
- Testing
- Efavirenz
- Volunteers
- 29,612 people
- Sponsor
- Bristol-Myers Squibb
AIDS, HIV Seropositivity
Investigation of the Psychosocial Factors Responsible for the Late Recourse to HIV Testing Within MSM
The present study will try to investigate and analyze the psycho-social hindrances and levers concerning the recourse to late HIV testing among the MSM population. This study is divided in two parts.
- Trial name
- ReTarD (NCT03661203)
- Testing
- Focus group, Individual interview, online self questionnaire
- Where
- 4 sites in France
- Volunteers
- 1,190 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
HIV/AIDS
Comparison of the Body Roundness Index and A Body Shape Index With Body Fat and Visceral Fat in People Living With HIV.
The study compares the Body Roundness Index (BRI) and the A Body Shape Index (ABSI) with with body fat and visceral fat in people living with HIV.
- Trial name
- NCT07203261
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Queens College, The City University of New York
Infection, Human Immunodeficiency Virus, HIV Infections
Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults
GSK2838232 is a novel HIV-1 maturation inhibitor (MI) that is being developed for the treatment of HIV-1 infection in combination with other antiretroviral therapy (ART).
- Trial name
- NCT03045861
- Testing
- GSK2838232, Cobicistat
- Where
- 14 sites in United States, Canada
- Volunteers
- 33 people
- Sponsor
- GlaxoSmithKline
HIV Infection
Drug Interactions Among Anti-HIV Agents
This study examined the interactions of various drugs used to treat HIV infection in order to design larger studies of possible combinations for people who continue to have high viral levels despite combination therapy.
- Trial name
- NCT00001766
- Testing
- Amprenavir, Efavirenz, Abacavir, Nelfinavir, Ritonavir
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV/AIDS, Hepatitis C
Project I Test: Implementing HIV Testing in Opioid Treatment Programs
This study will test two active evidence-based "practice coaching" (PC) interventions to improve opioid treatment programs' (OTPs') provision and sustained implementation of on-site 1) HIV testing and linkage to care and 2)…
- Conditions
- HIV/AIDS, Hepatitis C, Substance Use Disorders, Opioid-use Disorder
- Trial name
- NCT03135886
- Testing
- Information Control, HIV and HCV Testing Practice Coaching Intervention, HIV Testing Practice Coaching Intervention
- Where
- United States
- Volunteers
- 418 people, healthy volunteers welcome
- Sponsor
- Columbia University
HIV Testing, HIV Infections
Near Patient Study of the OraQuick ADVANCE® HIV-1/2 Rapid Antibody Test in Oral Fluid and Fingerstick Whole Blood
Point-of-care (POC) tests for HIV are easy to use, rapid and provide accurate results while the patient is still in-front of a healthcare provider (HCP).
- Trial name
- NCT04810559
- Testing
- OraQuick ADVANCE® HIV-1/2 Rapid Antibody Test
- Where
- 4 sites in Canada
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Unity Health Toronto
HIV Infections
Use of Amphetamine-type Stimulants & Its Relationship With HIV Incidence and Antiretroviral Adherence Among MSM and TG
There are two stages in the study. In Stage 1, 2000 Thai MSM, MSW and TGW/TGSW will be screened at the Thai Red Cross Anonymous Clinic (TRCAC) or Besides walk-in clients of TRCAC, potential participants could be referred to TRCAC…
- Trial name
- NCT03198962
- Where
- Thailand
- Volunteers
- 510 people, healthy volunteers welcome
- Sponsor
- Thai Red Cross AIDS Research Centre
HIV Infections, Lipodystrophy
SHARE: Simple HAART With Abacavir, Reyataz, and Epivir
SHARE: Simple HAART with Abacavir, Reyataz, and Epivir
- Trial name
- NCT00426296
- Testing
- atazanavir (Reyataz), ritonavir (Norvir)
- Where
- United States
- Sponsor
- Clinical Alliance for Research & Education - Infectious Diseases, LLC.
HIV Infections
A Phase I Safety and Immunogenicity Trial of the Facilitated HIV-1 Gag-Pol DNA Vaccine (APL-400-047, Apollon, Inc.) Given Intramuscularly by Needle and Syringe or Biojector 2000 Needle-Free Jet Injection System in HIV-1 Uninfected Adult Volunteers
To evaluate the safety, tolerability and immunogenicity in humans of the APL-400-047 vaccine when administered intramuscularly by needle and syringe at 1 of 3 doses or by Biojector at the intermediate dose.
- Trial name
- NCT00001088
- Testing
- APL 400-047, Bupivacaine hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, HIV Wasting Syndrome
A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome
To evaluate the safety, antiviral and anti-TNF-alpha activity, and preliminary efficacy of thalidomide in reducing weight loss in patients with HIV wasting syndrome.
- Trial name
- NCT00002127
- Testing
- Thalidomide
- Where
- 13 sites in United States
- Volunteers
- 75 people
- Sponsor
- Celgene Corporation
PTSD, Sexual Abuse
PTSD and Risk Behavior in HIV Positive Female Adolescents
This is a qualitative study using a purposive sampling methodology to interview HIV-positive female adolescents who have experienced physical and/or sexual abuse.
- Conditions
- PTSD, Sexual Abuse, HIV Infections
- Trial name
- NCT00271882
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of North Carolina, Chapel Hill
HIV Infections
HIV Prevention and PrEP Intervention for SGM Adolescents and Parents: "Hey, Friend"
In this 24-month pilot study, we will conduct the preparation phase of a multiphase optimization strategy (MOST) to develop a culturally appropriate (for Deep South contexts, to be adolescent friendly, and to be acceptable to…
- Trial name
- NCT04846946
- Testing
- Hey, Friend
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Virus-HIV
HIV A6 Genome In ART Unsuccessful Patients On DOR
The aim of the study is to evaluate the efficacy of Doravirine (DOR) in the second-line therapy for patients infected with HIV-1 sub-subtype A6 and its derivatives and having the mutations to previously used drugs
- Trial name
- HIV-A6-DOR (NCT05322083)
- Testing
- Doravirine
- Volunteers
- 60 people
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.